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Background: Hepatitis B virus (HBV), because of its error-prone viral polymerase, has a high mutation rate leading
to widespread substitutions, deletions, and insertions in the HBV genome. Deletions may significantly change viral
biological features complicating the progression of liver diseases. However, the clinical conditions correlating to the
accumulation of deleted mutants remain unclear. In this study, we explored HBV deletion patterns and their
association with disease status and antiviral treatment by performing whole genome sequencing on samples from
51 hepatitis B patients and by monitoring changes in deletion variants during treatment. Clone sequencing was
used to analyze preS regions in another cohort of 52 patients.
Results: Among the core, preS, and basic core promoter (BCP) deletion hotspots, we identified preS to have the
highest frequency and the most complex deletion pattern using whole genome sequencing. Further clone
sequencing analysis on preS identified 70 deletions which were classified into 4 types, the most common being
preS2. Also, in contrast to the core and BCP regions, most preS deletions were in-frame. Most deletions interrupted
viral surface epitopes, and are possibly involved in evading immuno-surveillance. Among various clinical factors
examined, logistic regression showed that antiviral medication affected the accumulation of deletion mutants (OR
= 6.81, 95% CI = 1.296 ~ 35.817, P = 0.023). In chronic carriers of the virus, and individuals with chronic hepatitis, the
deletion rate was significantly higher in the antiviral treatment group (Fisher exact test, P = 0.007). Particularly, preS2
deletions were associated with the usage of nucleos(t)ide analog therapy (Fisher exact test, P = 0.023). Dynamic
increases in preS1 or preS2 deletions were also observed in quasispecies from samples taken from patients before
and after three months of ADV therapy. In vitro experiments demonstrated that preS2 deletions alone were not
responsible for antiviral resistance, implying the coordination between wild type and mutant strains during viral
survival and disease development.
Conclusions: We present the HBV deletion distribution patterns and preS deletion substructures in viral genomes
that are prevalent in northern China. The accumulation of preS deletion mutants during nucleos(t)ide analog
therapy may be due to viral escape from host immuno-surveillance.
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Table 1 Clinical information of the LC/HCC group and the
CC/CH group
Features CC&CH LC&HCC P value
Count 33 18 -
Antiviral Therapy 14 (42%) 3 (17%) -
Age (mean ± SD) 33 ± 10 49 ± 12 <0.001
Gender (male%) 24 (73%) 14 (78%) 0.483
Genotype(C/B) 23/10 11/7 0.375
HBV-DNA > 107copies/ml 23 (70%) 9 (50%) 0.139
Deletion mutants 13 (39%) 7 (39%) 0.606
PreS deletion mutants 6 (18%) 5 (28%) 0.325
BCP deletion mutants 8 (24%) 3 (17%) 0.401
Zhang et al. BMC Microbiology 2012, 12:307 Page 2 of 10
http://www.biomedcentral.com/1471-2180/12/307Background
The high mutation rate of the hepatitis B virus (HBV) is
responsible for diverse viral mutants that are resistant to
antiviral therapies [1,2]. In addition to single base substitu-
tions, a number of deletion mutations have also been
reported. Deletion hotspots include precore/core genes,
the preS region, and the region of X gene overlapped with
basic core promoter (BCP) [3,4]. Deletions are believed to
be associated with the progression of viral hepatitis.
Coexistence of wild type HBV (wt), relative to deleted
sequences, and mutants with deletions in the C gene has
been shown to enhance viral replication, which may be
mediated by the coordination of wt and viral strains during
encapsidation or reverse transcription [5]. Core deletions
have frequently been detected before seroconversion to
anti-HBe [6]. Mutations in codons 130 and 131 of the X
gene, with deletions of nucleotides 1762 and 1764 respec-
tively, were reported to be common in hepatocellular
carcinoma (HCC) patients [7,8]. Furthermore, preS dele-
tion mutants produce truncated HBV surface proteins
(large and middle HBsAg (L- and M-HBsAg)), which accu-
mulate in the endoplasmic reticulum (ER). This has been
shown to increase ER pressure, which promotes the
expression of cyclin A and the host apoptosis suppressor
cyclooxygenase-2 [9,10]. These findings have raised
concerns regarding preS deletions as a risk factor for hepa-
tocarcinogenesis [11-14]. Despite certain complex viral
deletion patterns revealed in previous studies [4], we do
not yet fully understand the pattern of these deletions and
their correlation to clinical factors.
Many deletions interrupt epitopes of viral proteins recog-
nized by T- or B-cells. For instance, the internal deletion
around aa 81–136 of core antigen damages a T-cell epitope
[15,16]. PreS truncations were reported to be associated
with the loss of T- and B-epitopes that were able to elicit
host protective immune responses [17,18]. In addition,
deletions that disrupt the X gene may lead to low expres-
sion of HBcAg as observed by the lack of HBc antibody in
patients [19-21]. Hence, HBV deletions are speculated to
assist viruses in the evasion of immunologic surveillance.
Additionally, some deletion mutations are more frequently
observed in certain clinical conditions. For instance, an nt
1770–1777 deletion in the X gene of HBV was detected in
many serologically non-B and non-C patients [19,20].
However, most studies only investigate one or two deletion
hotspots, thus lacking the complete view of deletion
patterns provided by whole genome sequence analyses.
In this study, we describe the distribution of prevailing
deletions from 51 patient genomes and 70 genome frag-
ments with preS deletions obtained in northern China.
In particular, we detected significant correlation between
preS deletion and antiviral therapy. We also investigated
whether preS deletion mutants were resistant to antiviral
drugs based on an in vitro assay.Results
Deletion patterns in HBV genomes prevailing in northern
China
Full-length sequences were obtained from 51 patients
including 38 males and 13 females with a mean age of
38.2 ± 13.1 years. Among these, 12 were genotype B and
39 were genotype C (Table 1).
Of these 51 samples, genomic deletions were detected
in 39% (20/51). As shown in Figure 1A, the deletions
occurred almost exclusively in C, preS, and BCP regions
with lengths varying from 2 to 496 nt, whereas no dele-
tions were observed in the S gene, encoding the small
surface protein.
Next we analyzed deletion boundaries from all full-
length sequences. PreS deletions often occur around nt
2848-3215-56, whereas the C gene and BCP region tend
to lose nt 2148–2219 and nt 1758–1770, respectively
(Figure 1B-C). Deletion lengths in the BCP regions
appeared consistently in two patterns as either 8-10bp
(5/12) or 19-21bp (6/12).
The influence of deletions on viral proteins and the BCP
region
Of the three hotspots examined above, most deletions in
X/BCP (12/14) and the C gene (4/7) were frameshift
deletions, but almost all deletions in the preS (82/86)
were in-frame deletions. In addition, the P gene related
deletions never occurred at the reverse transcriptase
region, which is the target of all nucleos(t)ide analogues
(Figure 1A). The longest deletion (nt 2448–2934) shor-
tened the polymerase by a third and removed most of
the spacer and terminal protein domains.
The most significant consequence of sequence deletion
is the change of viral epitopes, in the core gene, the
majority of deletions altered epitopes of the C2 domain
(aa 84–101) of cytotoxic T lymphocytes (CTL) and the
B1 domain (aa 74–89) of B-cells (Figure 1B). As shown
in Figure 1C, the most frequently deleted fragment of
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Figure 1 Genome-wide deletion distribution of HBV in northern China. Upper panel: The nucleotide location of deletions along the viral
genome (X axis) and their counts (Y axis) in deletion mutations resolved from 51 whole genome sequences. Numbers at X indicate nucleotide
position with the EcoR1 site at the preS1 region as 0. Middle panel: The ORFs for all genes, 4 domains of the P gene, and the BCP region.
Bottom Panel: Alignment of detected deletions with viral epitopes in C (left) and the BCP/X region (right). 3 core deletions identified in clone
sequencing were also included in addition to 4 deletions observed in whole genome sequences. The two arrows (bottom right) stand for nt
1762 and 1764 position, respectively. Known B- and T-cell epitopes in the C protein [35] are numbered from N- to C-terminus.
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gets of HBxAg-specific humoral immune response P13
(aa121-135) and C3 (aa117-143) [22,23]. As illustrated in
Figure 2A, deletions in preS tend to affect t4, b8, b9 and
b10 epitopes. Interestingly, despite the fact that almost
all internal deletions of preS1 were localized at the b7
epitope (aa 72–78), far less truncations were seen in the
upstream region where most B- and T-cell epitopes were
clustered. The deleted domain in preS2 mutations
spanned the b10 epitope (aa 120–145) and a couple of
amino acids of the t5 epitope (aa 140–149), leading to
truncated MHBsAgs. Notably, in contrast with a previ-
ous study where immunosuppressed patients showed
lower preS2 deletion frequency, truncated preS2 mutants
were most frequently observed in patients with preS
deletions in our cohort.
Furthermore, most deletions in BCP occurred in
non-coding regions without interrupting the transcrip-
tion initiation site (nt 1793) of precore mRNA. The
frequently reported single point mutations at nt 1762
(A) and 1764 (G), known to affect binding of BCP to
liver-specific transcription factors that consequently
reduce HBeAg expression, were included in most BCPdeletions (10/14) (Figure 1C). However, patients with trun-
cated BCP were actually HBeAg-positive, implying the co-
existence of wt strains and possible coordination between
wt and deletion mutants as evidenced by the existence of
~30% of wt detected during clone sequencing.
Substructure of PreS deletions
As demonstrated in Figure 2A, the length and position
of deletions in preS exhibited very diverse patterns. To
explore the structural features of these mutations, we
further amplified the preS region from a second cohort
of 52 individuals and 70 preS deletions were obtained in
clone sequencing. These truncations can be grouped
into four categories, including a start codon defect of
the L protein (I), an internal deletion of preS1 (II), a
start codon defect of the M protein (III), an internal
deletion of preS2 (IV), and complex patterns containing
more than one deletion type (Figure 2B). Among these
mutants, internal deletions of preS2 were the most com-
mon (37%, 26/70). Furthermore, nearly half (9/19) of the
strains with type I deletions lost the same fragment
(nt2848-2865). Also, more than half (9/16) of type III dele-



































































Figure 2 Fine mapping of preS deletions. A. Alignment of detected preS deletions in HBV spreading in northern China (upper panel) with the
mutations in the same region from 6 immune-suppressed kidney-transplant patients from a previous study (middle panel) [4]. Known B- and
T-cell epitopes in the preS region [18] are numbered from N- to C-terminus. Note the dramatic difference in deletion break points of preS2 and
the higher deletion frequency at the 50 terminus of preS1 between the two sample groups. The T- and B-cell epitopes of surface proteins are
indicated in the bottom panel. B. PreS deletion patterns and their frequencies (right bars in black) in HBV prevailing in northern China. Sorting of
70 mutant clones resulted in four single patterns (I-IV) and four complex patterns as type I, start codon defect of L protein; type II, internal
deletion of preS1; type III, start codon defect of M protein; and type IV, internal deletion of preS2. Gray bars indicate deletion positions. Blunt
terminuses illustrate consistent break points and dotted edges display variable ends of deletions. Dashed lines show start codons in preS1 and
preS2. Bars in black, right panel: The counts of different deletion patterns.
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Particularly, preS2 deletions had a variable 50 terminus and
fixed 30 end (nt 54 to nt 56).
Type I and III deletions (34/70) also interrupted the
start codons of surface proteins, leading to abolishment
of LHBsAg or MHBsAg in 53% (18/34) and 44% (15/34)of cases respectively, with the remaining case (1/34)
showing a complex deletion pattern, resulting in the loss
of both antigens. In addition, we also detected a single
base mutation, ATG to ATA, in preS2 from deletion
mutants (5/70), resulting in the inability to produce M
protein instead of making a truncated one. Therefore,
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start codon led to the total abolishment of M protein
production in 30% (21/70) of cases.
Correlation of deletions with antiviral treatment
Next, we investigated a possible correlation between
antiviral treatment and deletion patterns and analyzed
clinical data of all dominant strains of quasispecies
(Table 1). Logistic regression analysis illustrated the
relationship between deletions and clinical factors
including age, gender, diagnoses, genotypes, HBV DNA
titers, and antiviral medication. Among all clinical fac-
tors examined, as summarized in Table 2, only antiviral
treatment played a role in the accumulation of deletion
mutations (Odds ratio [OR] = 6.81, 95% confidence
interval [CI] = 1.296 ~ 35.817, P = 0.023). In addition,
as shown in Table 1, we did not observe a higher over-
all deletion rate in advanced liver diseases (LC and
HCC) as reported by other studies, possibly due to lim-
ited cases of HCC.
Further comparison between sample groups also
demonstrated that individuals with antiviral therapy
showed a higher occurrence of deletions compared to
the untreated group (P = 0.005, FET, Figure 3). A similar
result was seen when the analysis was applied only to
chronic carrier (CC) and chronic hepatitis (CH) patients
(P = 0.007, fisher exact test (FET), Figure 3) when the
possible contribution of mutant accumulation in
advanced liver diseases was removed. When stratifying
each deletion hotspot by antiviral therapy, BCP dele-
tions were more common in patients with interferon
therapy (P = 0.018, FET Figure 3), whereas deletions in
preS, particularly in the preS2 region, were more likely
to be found in cases with nucleotide analog (NA) treat-
ment (P = 0.023, FET, Figure 3). In addition, sequencing
data of the preS clones from the second batch of 52
individuals support the full-length analysis results. Of
10 CH patients containing preS2-deleted viruses detected
by clone sequencing, 5 had received NA treatment, while 2
were treated with Interferon-alpha (IFN-α). Meanwhile, no
significant difference in deletion occurrence was found
between different genders (P = 0.608, FET) or genotypesTable 2 The correlation between host factors and the occurre
Predictor B S. E.
Age 0.016 0.035
LogHBV_DNA 0.075 0.328
Gender (Male/female) −0.534 0.766
Group (LC&HCC/CC&CH) 0.257 0.986
Genotype (C/B) −0.351 0.83
Antiviral Therapy (Treated/untreated) 1.919 0.847
B, regression coefficient; S.E., Standard Error; *, P < 0.05; OR, odds ratio; CI, confiden(P = 0.450, FET). In addition, two out of three preS2 dele-
tion mutants in the antiviral group had known antiviral
resistance mutations, M204I and L180M, respectively.
Dynamic accumulation of preS deletion mutants in HBV
quasispecies during ADV treatment
The above results suggest that NAs may contribute to the
accumulation of preS deletion mutants in quasispecies of
CH patients. To further verify NAs’ selection in this region,
we collected blood samples from two CH patients before
and after about 3 months of ADV treatment. Serial samples
were also collected from additional CH and LC patients, in
intervals of 2.5 months and 5 months respectively, with no-
antiviral treatment as the control. PCR direct sequencing of
the preS region showed heterogeneous indels in the two
samples collected after ADV treatment, whereas no
deletion signal was seen before treatment or in the
no-treatment controls. Furthermore, clone sequencing was
performed in two samples showing heterogeneous indels.
As demonstrated in Table 3, quasispecies analysis indicates
that about half of the strains contain preS deletions in these
two patients.
No antiviral resistance resulted from preS2 deletion alone
Next, we investigated if deletions alone could directly
lead to antiviral resistance. Two preS2 deletions with
high occurrence rates were introduced into the wt strain
in a plasmid followed by treatment with lamivudine,
adefovir, entecavir and tenofovir. As shown in Figure 4
and Additional file 1: Figure S1A-D, both preS2Δ1 and
preS2Δ2 showed similar sensitivity to the wt strain for
all four drugs. Since the wt strain in the plasmid was
genotype D whereas our data were mainly from geno-
type C strains, we further tested a similar preS2 mutant
using the genotype C plasmid and obtained the same
result (data not shown). Therefore, these preS2 deletion
mutants alone did not have antiviral resistance.
We further compared the replication abilities of these
strains in the absence of antiviral drugs, using HBsAg as
the internal standard. Compared to the wt strain (100%),
both mutants demonstrated slightly higher replication cap-
acities (preS2Δ1,117%; preS2Δ2, 107%), however,nce of deletions by logistic regression analysis
Wald
χ2
p OR 95.0% CI
Lower Upper
0.21 0.646 1.016 0.948 1.089
0.052 0.819 1.078 0. 567 2.051
0.487 0.485 0.586 0.131 2.629
0.068 0.794 1.293 0.187 8.928
0.179 0.672 0.704 0.138 3.577
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Figure 3 Deletion mutations and antiviral treatments. The profiles of different types of HBV deletions between patients with (+) and without
(−) antiviral therapy based on 51 HBV full-length sequences. Upper panel: analysis from all samples of CC, CH, LC, and HCC. Lower panel: analysis
without patients of progressive liver diseases. Antiviral medication was grouped as nucleotide analog only (left), IFN only (middle), and either one
or both (right). Each deletion and the ratio of wt virus to mutants were labeled under the histogram.
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Figure S1E).
Discussion
Deletion patterns in the preS region upon host response
to viral infection
We analyzed deletions in HBV genomes with respect to
deletion hotspots and their boundaries, the correlation
of mutations to antiviral medication, and the structural
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N, no deletion detected; D, deletion detected.in our samples with those in immuno-suppressed
patients reported by Preikschat et al. [4]. Similar deletion
patterns in C, BCP, and preS1 regions were observed
and one of the major differences was the deletion
frequency in preS2 (Figure 2A). Among all deletions in
the entire preS region, truncations in preS2 were the
most common in our investigation, suggesting that the
preS2 region may be selectively affected by immune
pressure. Further studies are needed to clarify the role
played by the host immune response in inducings during ADV treatment
End
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D aa 65–78 (peS1),
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Figure 4 Constructed preS2 mutants and their sensitivity to antiviral drugs. Two deletions illustrated at the top were introduced into the
wt genome in a plasmid, respectively. Constructed mutants were transfected into Huh7 cells with or without antiviral drug treatment as indicated
in each plot. The viral replication level in a culture medium without drugs was denoted as 100%. The curves indicate the decrease in viral
replication with increasing drug concentrations and the preS2 deletion alone did not change the mutants’ sensitivity to antiviral drugs. The
crossover points between the horizontal line and the curves indicate the IC50 for each strain. *similar viral replication data of the Δ2 mutant with
drug treatment is shown in Additional file 1: Figure S1.
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phenomenon is the high rate of deletions in the 50
terminus of preS1 in our samples compared to immune-
suppressed subjects as shown in Figure 2A. Although it
does not encode any known epitope, this region spans
the host determining region which contributes to the
species specificity of HBV [24]. Interestingly, genotype
D of HBV, which is 11 amino acids shorter than that of
genotype B, does not contain this region and resembles
the 50 terminus of the preS1 deletion mutant [25].
PreS2 deletions may promote HBV immune escape after
recovery of host immune function following antiviral
treatment
Deletions have been shown to confer resistance to lamivu-
dine (LMV) in an HIV-related study, and certain deletion
mutants of HBV were shown to be insensitive to LMV
[26,27]. In our study, we observed the accumulation of preS
deletions correlating to antiviral therapy. However, our
in vitro experiments demonstrated that the HBV with preS
deletion alone did not confer resistance to antiviral therapy
in such mutants, similar to a recent observation by Ohkawa
et al. [28].
This inconsistency between the epidemiological statistics
and in vitro experiments is perhaps not surprising when
the most common feature of HBV infection, the existence
of quasispecies within an individual, is considered. Despitevery complex patterns of HBV quasispecies, which were
resolved by clone sequencing or high throughput sequen-
cing, we, along with others, have observed that the wild
type never disappears from the viral composition. For
instance, our recent pyrosequencing study on HBV quasis-
pecies showed that the lowest proportion of the wt strain in
patients was around 1% (Zhang et al., unpublished). These
data strongly suggest the coordination of wt and various
types of mutants which may not survive by themselves
alone but whose presence may be beneficial to the viral
population in vivo.
Such coordination between viral strains may well explain
our results. Generally speaking, antiviral therapy would also
result in the recovery or enhancement of the host defense
system, which in turn would increase the selection pressure
on mutants, such as preS deletions, that may promote
immune escape. Supporting evidence also stems from
research that suggests an improvement in CTL responsive-
ness to HBV in CH patients following LMV treatment [29].
In addition, conventional vaccination combined with clevu-
dine could help the host to overcome immunologic tole-
rance and restore T-cell responses to surface proteins
according to the woodchuck model [30]. For instance,
viruses with truncated or abolished M protein may survive
due to the disruption of their epitopes. Interestingly, we
observed a much higher frequency of preS2 deletions in
patients treated with NAs compared to long-term
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suggesting increased immune escape in preS2 deletion
mutants. In particular, almost all truncated preS2 mutants
had a damaged b10 epitope (aa 120–145), a major envelope
epitope whose absence would inhibit HBV clearing by the
host [31,32]. Therefore, larger sample sizes and detailed
functional analysis will be required for further verification.
Meanwhile, considering the virulent feature of preS dele-
tion mutants in chronic hepatitis infection, development of
diagnostic tests for various deletion mutants would be
beneficial for CH patients.
Conclusions
In this study, we characterized deletion patterns in three
hotspots, along the whole HBV genome, that are preva-
lent in northern China. Except for the BCP region,
which influences regulating elements of the core gene,
most deletions appear to destroy various epitopes of
viral proteins. A comparison of samples with or without
antiviral medication demonstrated a correlation between
NA treatment and preS deletions, which is also evi-
denced by the analysis of serial samples before and after
ADV treatment. Although preS deletions alone had no
effect on drug resistance, the accumulation of preS dele-
tion mutants in patients during antiviral treatment may
promote viral immune escape.
Methods
Patients and blood samples
Blood samples were provided by You’an Hospital in Beijing.
This study was approved by the Institutional Review Board
of the Beijing Institute of Genomics and the Ethics
Committee of Beijing You’an Hospital of Capital Medical
University. Informed consent was obtained from all
patients. Patients were diagnosed as chronic carrier (CC),
chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellu-
lar carcinoma (HCC) according to the guidelines on the
prevention and treatment of chronic hepatitis B in China
(2010) [33]. No patients had co-infections with HCV,
HDV, or HIV. Blood samples of 5ml were collected,
cells and sera were then separated and stored at −20°C.
From the few hundred stored samples, we successfully
amplified and sequenced 51 whole genomes from 51
individuals. Additionally, preS clone sequencing was
performed in another cohort of 52 patients for fine
mapping of deletion substructure.
DNA quantification and HBV serological marker detection
Viral DNA titers were quantified using the FQ-PCR Kit
for HBV (DaAn Gene Co., Guangdong, China) on a
GeneAmp 5700 Sequence Detection System (PE Applied
Biosystems, CA, USA). Serological markers were deter-
mined by an Electrochemiluminescence Immunoassay on
a Roche E170 Modular Immunoassay Analyzer (RocheDiagnostics, Mannheim, Germany) following the manu-
facturer’s protocol.
Viral DNA extraction and amplification
Viral DNA was extracted from 400 μl sera per sample
using the QIAamp MinElute Virus Spin (Qiagen, Hilden,
Germany). All DNA samples were stored at −20°C.
Whole genome amplification was performed using LA
Taq (Takara, Osaka, Japan) according to the method
described by Günther et al., with the primers for P1
(1821 to 1841), CCGGAAAGCTTGAGCTCTTCTTTTT
CACCTCTGCCTAATCA, and P2 (1823 to 1806), CCG
GAAAGCTTGAGCTCTTCAAAAAGTTGCATGGTG
CTGG [34]. The lowest DNA amount required for ampli-
fication was 103 copies/ml in our experimental system.
Sequencing primers are listed in Additional file 1: Table S1,
and the primers SP5 and SP9 were also used for preS
region amplification. Hot start PCR for the preS region
was performed with the following cycle: 95°C for 2 min-
utes and 30 seconds, followed by 35 cycles of denaturation
at 94°C for 1 minute, annealing at 58°C for 90 seconds,
and elongation at 72°C for 3 minutes. All reactions were
performed on a PTC-200 Peltier Thermal Cycler (MJ
Research, MA, USA).
Viral DNA sequencing
After purification via the Montage PCR96 column
(Millipore, MA, USA), PCR products were sequenced
on a Prism 3730 (ABI, USA). Contigs were assembled
using SeqMan (DNAstar 5.0, WI, USA), and sequences
were aligned using ClustalW for further analysis. All
mutations were checked manually. Whole genomes
mentioned in this study are defined as >97% of full
length and sequencing gaps at the end of the genome
have no overlaps with deletion hotspots.
The boundaries of deletion regions that appeared in the
sequencing electropherogram were determined by reading
from both directions. The regions of interest were amplified
by PCR and the products were cloned into a pMD18 T
vector (Takara, Osaka, Japan) followed by sequencing of
5–10 positive clones per sample. NCBI accession numbers
for all sequences are listed in Additional file 1: Table S2.
Construction of HBV mutants and examination of their
antiviral resistance
Candidate deletions were introduced into the HBV-
expression plasmid Yi026-pcDNA3.1/Zeo(−) using the
QuikChangeW Site-Directed Mutagenesis Kit (Stratagene,
CA, USA). The plasmid, harboring a 1.1X overlength
genome of HBV (ayw), was kindly provided by Yi Ni
and Stephan Urban from the University of Heidelberg
(Heidelberg, Germany). Introduced mutations were
verified by plasmid re-sequencing.
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cells/dish, reaching around 90% confluency before transfec-
tion the following day. Cells were transfected using 24 μl
FuGENEWHD (Roche, IN, USA)) reagent with 8 μg of plas-
mid DNA. 16–20 h post-transfection, transfected cells were
washed twice and then seeded into a 96-well plate at
3 × 104 cells/well. The cells were treated with serial dilu-
tions of four drugs in fresh medium for 3 days, including
lamivudine (LMV), adefovir (ADV), entecavir and tenofovir
(Sequoia Research Products Limited, UK). The superna-
tants were collected after centrifugation at 1500 × g for 5
min, and then prepared for HBV DNA extraction using the
BioSprint 96 One-For-All Vet Kit (Qiagen, Hilden,
Germany). Half maximal inhibitory concentrations (IC50)
were calculated for each construct where the resistance
factor is calculated as the IC50 of mutant divided by the
IC50 of the wt strain. The amount of HBsAg produced by
each strain was determined by the AxSYM HBsAg assay
(Abbott Laboratories, IL, USA).
Statistical analysis
SPSS 13.0 was used for logistic regression analysis, t-tests
and Fisher exact tests (FET).
Additional file
Additional files 1: Figure S1. Antiviral resistance examination for the
preS2Δ2 mutant. Table S1. Primer sequences. Table S2. Accession
numbers for nucleotide sequences.
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